- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01101217
Effect of Zinc Suplementation on Serum Hemosystein Level in Hemodialysis Patients
April 8, 2010 updated by: Shiraz University of Medical Sciences
The purpose of this study is to study the effect of zinc supplementation in end stage renal failure on hemocystein level.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
hemocystein increased in end stage renal failure and zinc involved in hemocystein metabolism thus zinc supplementation may be effective on hemocystein level.
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Fars
-
Shiraz,, Fars, Iran, Islamic Republic of, 098
- Shiraz University Hemodialysis Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- hemodialysis for 3 months
- older than 18 years old
- serum level of zinc less than 72.6 microgram/ l in men and less than 70 microgram/ l in female
Exclusion Criteria:
- acute renal failre
- malabsorption
- history of steroid or cytotoxic consumption
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo
placebo for 6 weeks
|
placebo daily for 6 weeks
|
Active Comparator: zinc
zinc sulfate 220 mg per day orally for 6 weeks
|
in 50 patients zinc sulfate 220 mg per day orally for 6 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
decreased hemocystein level
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2009
Study Completion (Actual)
September 1, 2009
Study Registration Dates
First Submitted
April 8, 2010
First Submitted That Met QC Criteria
April 8, 2010
First Posted (Estimate)
April 9, 2010
Study Record Updates
Last Update Posted (Estimate)
April 9, 2010
Last Update Submitted That Met QC Criteria
April 8, 2010
Last Verified
January 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4542
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End Stage Renal Failure
-
Peripal AGUniversity Hospital Birmingham NHS Foundation Trust; Swiss Federal Institute...CompletedRenal Failure | Peritoneal Dialysis | Renal Replacement Therapy | End Stage Renal Failure on Dialysis | End Stage Renal Disease on DialysisUnited Kingdom
-
The University of Hong KongHospital Authority, Hong KongCompletedEnd-stage Renal Failure (ESRF)Hong Kong
-
Sykehuset TelemarkOslo University HospitalActive, not recruitingQuality of Life | End Stage Renal Disease | End Stage Renal Failure on DialysisNorway
-
The Hong Kong Polytechnic UniversityHospital Authority, Hong KongCompletedPalliative Care | Renal Failure, End-stageHong Kong
-
Guy's and St Thomas' NHS Foundation TrustKing's College LondonCompleted
-
Dialysis Outcomes Heart Failure Aldactone Study...CompletedEnd-stage Renal FailureJapan
-
GuerbetCompleted
-
University Hospital, MontpellierAider Montpellier : Dr Chalabi Lofti; Aider Cèvennes et Confins Rhodaniens... and other collaboratorsUnknown
-
Northwestern UniversityNovartisCompletedEnd Stage Renal Failure With Renal TransplantUnited States
-
Helsinki University Central HospitalUniversity of Helsinki; Academy of FinlandUnknownEnd Stage Renal Failure With Renal TransplantFinland
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States